candesartan cilexetil and Dyslipidemias studies

candesartan cilexetil and Dyslipidemias

candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects

Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.

Research Excerpts

Excerpt	Relevance	Reference
"We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension."	2.72	Feasibility of treating prehypertension with an angiotensin-receptor blocker. ( Black, HR; Egan, BM; Grimm, RH; Julius, S; Kaciroti, N; Messerli, FH; Michelson, EL; Nesbitt, SD; Oparil, S; Schork, MA; Weber, MA, 2006)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

2 (100.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Julius, S	1
Nesbitt, SD	1
Egan, BM	1
Weber, MA	1
Michelson, EL	1
Kaciroti, N	1
Black, HR	1
Grimm, RH	1
Messerli, FH	1
Oparil, S	1
Schork, MA	1
Mann, J	1

Studies

Julius, S

Nesbitt, SD

Egan, BM

Weber, MA

Michelson, EL

Kaciroti, N

Black, HR

Grimm, RH

Messerli, FH

Oparil, S

Schork, MA

Mann, J

Clinical Trials (1)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients With High Normal Blood Pressure (TROPHY)[NCT00227318]	Phase 3	1,000 participants	Interventional	1998-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients With High Normal Blood Pressure (TROPHY)[NCT00227318]

Phase 3

1,000 participants

Interventional

1998-07-31

Completed

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for candesartan cilexetil and Dyslipidemias

Article	Year
Feasibility of treating prehypertension with an angiotensin-receptor blocker. The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe	2006

Article

Year

Feasibility of treating prehypertension with an angiotensin-receptor blocker.

The New England journal of medicine, 2006, Apr-20, Volume: 354, Issue:16

Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe

2006

Other Studies

1 other study available for candesartan cilexetil and Dyslipidemias

Article	Year
[Treatment of high-normal blood pressure with angiotensin receptor blockers. TROPHY Study (Trial of Preventing Hypertension)]. Der Internist, 2007, Volume: 48, Issue:4 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe	2007

Article

Year

[Treatment of high-normal blood pressure with angiotensin receptor blockers. TROPHY Study (Trial of Preventing Hypertension)].

Der Internist, 2007, Volume: 48, Issue:4

Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe

2007